Professional Documents
Culture Documents
Nonfunctional Pancreatic Neuroendocrine Tumors Surg Clin N Am 2014
Nonfunctional Pancreatic Neuroendocrine Tumors Surg Clin N Am 2014
N e u ro e n d o c r i n e Tu m o r s
Jennifer H. Kuo,
MD
, James A. Lee,
MD
b,
*, John A. Chabot,
MD
KEYWORDS
Pancreas Neuroendocrine Nonfunctional Neuroendocrine liver metastases
PanNET
KEY POINTS
Pancreatic neuroendocrine tumors are rare, heterogeneous tumors that compose 3% of
all pancreatic neoplasms and 7% of all neuroendocrine tumors.
The incidence of pancreatic neuroendocrine tumors has been increasing over the past
20 years because of the increased diagnosis of pancreatic incidentalomas.
Ninety percent of pancreatic neuroendocrine tumors are nonfunctional tumors that are
often malignant and present with symptoms of mass effect or metastatic disease.
Formal surgical resection is the treatment of choice for most locoregional disease; however, surgical decision making must include many variables.
Hepatic metastasis is common, and resection is recommended in the absence of extrahepatic disease.
Interventional liver-directed therapies and targeted systemic therapies offer promising alternatives for patients with advanced disease, improving morbidity and increasing
progression-free survival.
INTRODUCTION
Neuroendocrine tumors (NETs) are a group of rare, diverse neoplasms, which can be
found throughout the body. They are most commonly located in the gastrointestinal
tract and lung but are also found in the pancreas.1 Historically known as islet cell tumors, they are now classified as pancreatic NETs (PanNETs) by the World Health Organization (WHO). When compared with adenocarcinomas, PanNETs account for a
relatively small percentage of pancreatic neoplasms,2,3 but their incidence has been
increasing over the past 20 years. Based on the Surveillance, Epidemiology, and
End Results (SEER) database, the incidence of NETs in the United States increased
a
Division of GI/Endocrine Surgery, Columbia University, 161 Fort Washington Avenue, 8th Floor,
New York, NY 10032, USA; b COACH Education, Endocrine Surgery, Adrenal Center, New York
Thyroid/Parathyroid Center, Simulation Center, Columbia University, 161 Fort Washington
Avenue, 8th Floor, New York, NY 10032, USA
* Corresponding author.
E-mail address: jal74@columbia.edu
690
Kuo et al
nearly 5-fold over the past 3 decades and was 5.25 per 100,000 in 2004.4 PanNETs
account for 7% of all NETs5 and have an incidence of 0.43 per 100,000 people in
2007,5 a greater than 2-fold increase in the incidence of PanNETs since the 1980s.
The increased frequency of abdominal imaging, specifically computed tomography
(CT) and ultrasound, has increased the incidence of abnormal pancreatic findings
detected in asymptomatic patients. Of these patients, 17% will ultimately undergo
pancreatectomy.6 This increase in pancreatic incidentalomas may reflect a historical
underestimation of the prevalence of this disease; autopsy studies suggest that the
prevalence of PanNETs may be higher than we expect, with prevalence rates of 3%
to 10%.79
RELEVANT ANATOMY/PATHOPHYSIOLOGY
Traditionally, PanNETs have been thought to arise from the islets of Langerhans that
perform the endocrine function of the pancreas. More recent investigation, however,
has demonstrated that these neoplasms originate from pluripotent cells in the
pancreatic ductal/acinar system.10 All PanNETs express neuroendocrine markers,
such as synaptophysin, neuron-specific enolase, and chromogranin A (CgA) (present
in 88%100% of patients with PanNETs). A multitude of cellular and molecular alterations have been implicated in the pathogenesis of PanNETs, involving at least
14 different types of cells and genetic alterations in the MEN-1 gene, the p16/MTS1
tumor-suppressor gene, the DPC4/Smad 4 gene, amplification of the Her-2/neu
proto-oncogene, and alterations in transcription factors Hox C6, growth factors,
and their receptor expressions.11 Several of these genetic alterations have been
shown to correlate with tumor aggressiveness and may have prognostic significance.12 This molecular heterogeneity translates to heterogeneity in the clinical presentation, including both the multiple syndromes of overproduction and
hypersecretion of hormones that have traditionally characterized these tumors as
well as hormonally silent tumors. Thus, PanNETs are often classified as functional
or nonfunctional based on the presence or absence of a particular clinical syndrome
associated with hormone hypersecretion. According to the SEER database, from 1973
to 2000, most PanNETs diagnosed were nonfunctional tumors (90.8%); the remaining
9% included malignant functional tumors, such as gastrinomas (4.2%), insulinomas
(2.5%), glucagonomas (1.6%), and VIPomas (0.9%).13,14 In addition to variability in
the production of pancreatic endocrine hormones, PanNETs exhibit a broad range
of growth rates, malignant potential, and overall prognosis. Although commonly
perceived to be indolent tumors because they have a far better prognosis than pancreatic adenocarcinoma, most patients with PanNETs (60%70%) present with metastatic disease.4,13,14 Even when they are resectable, many patients ultimately succumb to
the disease. Following surgical resection of PanNETs, the 5-year survival for PanNETs
other than insulinomas is roughly 65%, with a 10-year survival of 45%.14
In 2000, the WHO introduced a classification system based on clinical and histopathologic features that divides PanNETs into well-differentiated endocrine tumors
with either benign or uncertain behavior, well-differentiated endocrine carcinomas,
or poorly differentiated endocrine carcinomas.15 More recent classification systems
have acknowledged the increasing importance of a proliferative index, specifically
expression of the nuclear antigen Ki-67, and evidence of its prognostic value for
PanNET.1517 In 2010, the WHO revised the classification of PanNETs to reflect
a proliferation-based grading system in conjunction with the traditional histopathologic diagnostic criteria (Table 1). They delineated a 3-tier grading system of
PanNETs designating tumors as well-differentiated NETs versus poorly differentiated
Table 1
WHO classification of PanNETs
Grade
G1
2
<2
G2
320
220
G3
>20
>20
TNM
Size (cm)
T1a
<1
T1b
12
T2
>2
In the World Health Organization (WHO) 2010, the higher grade is assumed if the Ki-67 index and
mitotic count differ; in the WHO 2010 TNM, the tumor is classified as T2 if it is larger than 2 cm in
diameter or if it invades the muscularis propria. T3 and T4 tumors are locally aggressive tumors
(data not shown in the table).
Abbreviation: HPF, high-power field.
Data from Bosman F, Carneiro F, Hruban R, editors. WHO classification of tumors of the digestive
system. Lyon (France): IARC Press; 2010.
Most PanNETs are sporadic and tend to affect older individuals. Men have a slightly
increased risk of developing PanNETs than women (55.2% vs 44.8%), and there
is a Caucasian predominance in the United States (84.1% Caucasian vs 15.9% other
background).13 Functional tumors present with symptoms that result from the
specific hormone being elaborated. The most common functional PanNETs are insulinomas composing 30% to 45% of functioning PanNETs2,21 and gastrinomas
composing 16% to 30%.21 Glucagonoma, VIPomas, and somatostatinomas are
rarer PanNETs, and other rare functional PanNETs also exist.22 The presentation of
these tumors is summarized in Table 2 but is not discussed in further detail in this
article.
Patients with nonfunctional tumors typically present with symptoms related to local
mass effect or metastatic disease, indicating a more advanced stage of disease.9
691
692
Kuo et al
Table 2
Summary of functional NETs
Tumor Type
Numbera
Secretory Hormone
Clinical Features
Laboratory Tests
Symptomatic Treatment
Insulinoma
40%60%
Insulin
Hypoglycemia; symptoms of
catecholamine excess; 90%
benign
Dietary modifications;
octreotide; diazoxide
Gastrinoma
20%50%
Gastrin
Glucagonoma
Rare
Glucagon
Serum glucagon
Somatostatinoma
Rare
Somatostatin
Octreotide
VIPoma
Rare
Vasoactive intestinal
peptide
Choleralike, secretory
diarrhea; hypokalemia;
hypochlorhydria
Serum VIP
Octreotide
Abbreviations: GERD, gastroesophageal reflux disease; MEN-1, multiple endocrine neoplasia type 1; TPN, total parenteral nutrition; VIP, vasoactive intestinal
polypeptide.
a
Percentage among PanNETs.
Nonfunctioning tumors either do not produce any hormone, produce very small
amounts of hormones that are insufficient to produce symptoms, or produce hormones that do not generate specific symptoms (pancreatic polypeptide, human chorionic gonadotropin subunits, calcitonin, or neurotensin).23,24 Most nonfunctional
tumors occur in the head of the pancreas and often produce symptoms of mass effect
that mimic those of pancreatic adenocarcinoma, including jaundice, abdominal
pain, weight loss, abdominal mass, nausea and vomiting, backache, and pancreatitis.22,25,26 As previously mentioned, the number of pancreatic tumors discovered
incidentally before any onset of symptoms is dramatically increasing because of the
widespread use of abdominal imaging.6,9,23 Bruzoni and colleagues27 found that
19% of these pancreatic incidentalomas were NETs on the final pathology.
Although most PanNETs occur sporadically, nearly 10% are associated with predisposing genetic syndromes. These hereditary syndromes include multiple endocrine
neoplasia type 1 (MEN-1 syndrome), von Hippel-Lindau disease (VHL), von Recklinghausen disease or neurofibromatosis type 1 (NF-1), and tuberous sclerosis complex
(TSC).2,9,14,21 These patients are generally diagnosed at a younger age, have multiple
synchronous lesions throughout the pancreas, and have a family history of endocrine
disorders or their associated cancers.9,21 The most recognized of these hereditary
syndromes is MEN-1.2,9,14,21 Most patients with MEN-1 (80%100%) develop
nonfunctioning PanNETs, 50% to 60% develop gastrinomas, 20% insulinomas, and
3% to 5% VIPomas or glucagonomas.2,9,14,21 Nonfunctional PanNETs, cystic pancreatic lesions, and mixed serous-NETs can be seen in 20% of patients with VHL.2,14,21 In
contrast to MEN-1 and VHL, PanNETs are relatively uncommon in patients with NF-1
and TSC (<10%).2,14,21
The evaluation of patients with PanNETs should include a comprehensive history
assessing for signs or symptoms of tumor mass effect, metastatic disease, or specific
functioning tumors. Eliciting a family history or genetic testing can determine whether
the tumor is sporadic or associated with a genetic syndrome and can have a significant impact on preoperative planning. For example, patients with MEN-1 are more
likely to have multiple tumors throughout the pancreas necessitating altered surgical
planning.
DIAGNOSIS
When a tumor of neuroendocrine origin is suspected, a complete biochemical evaluation looking for the most commonly secreted pancreatic hormones should be performed to determine functionality. Levels of NET markers can be very helpful for
diagnosis and determining the prognosis of nonfunctional PanNETs.2,11 Serum chromogranin A, a 49-kd protein contained in the neurosecretory vesicles of the NET cells,
is the most widely used as it reflects tumor burden. It is most helpful for welldifferentiated NETs. Elevated plasma chromogranin A levels have been associated
with a poor overall prognosis, and early decreases may be associated with favorable
treatment outcomes. It can be helpful in screening for persistent, recurrent, or metastatic disease11; the recent North American Neuroendocrine Tumor Societys management guidelines recommend following chromogranin A levels in patients with
advanced disease and in patients who have elevated CgA levels at diagnosis and to
consider following levels in those who have undergone resection.18 Elevated CgA
levels can also be caused by renal or liver failure and the use of proton-pump
inhibitors.
The PP cells of the islets of Langerhans secrete pancreatic polypeptide. It is found to
be elevated in 63% of PanNETs28 but has not been widely used because of its low
693
694
Kuo et al
The diagnosis of PanNETs centers on biopsy and staging of the disease. Crosssectional imaging studies with either a multiphasic CT scan or magnetic resonance imaging (MRI) dedicated to the evaluation of the pancreas play a key role.
CT
Uses indium- 111-labeled somatostatin analogue resulting in high-resolution imaging of the pancreas
Effective for visualizing gastrinomas (100%), glucagonomas, and nonfunctioning
pancreatic tumors
Not sensitive for detection of insulinomas and poorly differentiated NETs
Additional advantage of whole-body scanning allowing for detection of metastatic disease outside of the abdomen (Fig. 2)
Provides functional information on level of somatostatin receptor expression,
which may be used to guide somatostatin-based therapies in patients with
advanced disease
Does not provide information on tumor size or surgical resectability
Accuracy improved with fusion of somatostatin analogues to positron emission
tomography isotopes in single-photon emission CT; allows differentiation between areas of pathologic and physiologic uptake in the abdomen
Fig. 3 provides a simple algorithm summarizing the diagnostic tests for PanNETs.
Other diagnostic procedures, including visceral arteriography and selective intraarterial stimulation, are used to localize occult functional tumors.
SURGICAL MANAGEMENT
Surgical resection is the only curative therapy for functional and nonfunctional
PanNETs and is the cornerstone of the treatment of patients with PanNETs without evidence of metastatic disease or significant comorbidities. There is a significant survival
benefit in patients with localized, regional, and metastatic disease who undergo resection (average overall survival 114 months vs 35 months) when compared with those
695
696
Kuo et al
Fig. 2. Somatostatin receptor scintigraphy (indium In 111 pentetreotide [Octreoscan]) allows whole-body imaging and is sensitive for detecting metastatic disease, especially
outside of the abdomen. It also allows assessment of somatostatin receptor expression levels
that can be used to guide systemic therapy.
who did not undergo surgery.40 Thus, surgical therapy should be considered if most
(approximately 90%) of the gross disease can be resected safely. The primary exception to this rule is PanNETs associated with MEN-1 and Zollinger-Ellison syndrome
whereby tumors tend to be multiple and nonfunctional and may warrant close surveillance and/or symptom management.
Given the variable biology and behavior of PanNETs, deciding on the appropriate
surgical therapy requires taking into account a myriad of factors, including risk of
malignancy, presence/absence of metastases, as well as the patients overall health
and wishes. Fig. 4 summarizes an algorithm that provides guidance on the surgical
treatment of patients with solitary PanNETs. In general, nonfunctional PanNETs
should undergo resection. However, evidence is emerging that with more accurate
pathologic analysis of biopsy material, there are situations when small lesions can
be observed. Most nonfunctional PanNETs are malignant as manifested by local invasion, lymph node involvement, and/or liver metastases. Patients without evidence
of metastatic disease should be treated with formal resection and lymphadenectomy. Patients with low-grade metastatic disease should be treated with surgical
resection (including resection of metastatic sites) in conjunction with adjuvant therapies, such as ablation, embolization, hormonal therapy, and chemotherapy. Patients
with high-grade metastatic disease should receive medical therapy, often including
cytotoxic chemotherapy.
All nonfunctional PanNETs greater than 3 cm should be resected if possible. Controversy exists as to whether enucleation is sufficient resection for nonfunctional
PanNETs smaller than 3 cm. In a retrospective review of 318 patients with sporadic,
nonfunctional, nonsyndromic PanNETs resected at a single institution, 9% to 37%
of tumors less than 3 cm in size were associated with lymph node metastases.
They also found on multivariate analysis that the presence of positive lymph nodes
conferred a poorer survival.41 Therefore, formal resection is preferred over enucleation
697
698
Kuo et al
Fig. 4. Decision tree for surgical resection of PanNET. PD, pancreatic duct. * Refer to text for
discussion of enucleation versus formal resection.
Table 3
Summary of operative management options for PaNETs
Procedure
Approach
Indications
Contraindications
Outcomes
Pancreaticoduodenectomy
Distal pancreatectomy
Open
Laparoscopic
Splenic preservation
contraindicated for patients
with suspected malignancy
Traditional resections
Enucleation
Open
Laparoscopic
Tumors 3 cm in size
Large tumors
Nodal or metastatic disease
Lesions in close proximity to
the pancreatic duct
Central pancreatectomy
Open
Laparoscopic
Better preservation of
pancreas function with
similar morbidity and
mortality43
Parenchyma-sparing resections
699
700
Kuo et al
concluded that randomized trials were needed to compare oncologic outcomes and
the cost-effectiveness of these procedures.
MANAGEMENT OF HEPATIC METASTASES
The liver is the predominant site of extranodal metastatic disease in PanNETs and is
the predominant cause of mortality in many patients. Resection of hepatic metastases
has been shown to improve outcomes in more than 90% of cases.11,5254 Survival
rates of approximately 60% are reported at 5 years after hepatic metastasectomy
compared with 30% in patients with untreated liver metastases,54,55 with a median
survival of 24 to 128 months. In patients without (or mild nonclinically significant)
extrahepatic disease, resection should be considered for treatment. Asymptomatic
patients who have resectable disease should also be considered for surgical debulking. Table 4 summarizes the interventional treatment options for hepatic metastases
in patients who are not candidates for surgical resection. In general, the use of these
treatments either alone or in conjunction with surgical resection is recommended for
locoregional control and symptom relief.5658 Liver transplantation is a viable option
for symptomatic, well-differentiated gastrointestinal NETs when standard surgical
resection is not an option or for disease that has not responded to other treatment options. The 5-year survival rate is 45%.59 However, a primary PanNET was found to be a
negative prognostic factor60; therefore, liver transplantation is not recommended in
the treatment of NETs arising from the pancreas.
SYSTEMIC THERAPY
Table 4
Summary of interventional liver-directed therapies for metastatic PaNETs
Indications
Contraindications
Approach
Outcomes
Prior
pancreaticoduodenectomy
Significant hepatic
insufficiency
Portal vein thrombosis
Poor performance status
Radiofrequency ablation,
microwave ablation, and
cryoablation
Large tumors
Infusional chemotherapy
Uncommon technique
Used in conjunction with
radiotherapy
Diffuse disease
Treatment
701
702
Kuo et al
Historically, well-differentiated PanNETs have been resistant to standard chemotherapy, with reported response rates varying from 8% to 45%.69 Because of the
limited efficacy of these agents, they were often started when patients demonstrated
progressive disease despite somatostatin analogues. More recently, a randomized
trial comparing the combination of streptozocin with doxorubicin versus streptozocin
with fluorouracil demonstrated a mortality benefit as well as radiological and biochemical regression of disease in 69% of patients.70 Therapy with streptozocin is limited by
its toxicity and cumbersome administration schedule. Oral temozolomide (an alkylating agent) is better tolerated and has been shown to have comparable efficacy.70 An
18-month median progression-free survival in patients with metastatic PanNETs was
demonstrated in patients who received temozolomide and capecitabine.62 Cytotoxic
therapies should be considered in the palliation of patients with advanced PanNETs
and symptoms related to tumor bulk.
Targeted Therapy
NETs have been shown to express a multitude of growth factors and their corresponding receptors leading to the development of targeted therapeutic agents. Recent
phase III studies have shown tremendous promise for 2 drugs designed for targeted
therapy in the treatment of PanNETs, everolimus and sunitinib. Both drugs are recommended for patients with progressive metastatic PanNETs.
Everolimus
Sunitinib
703
704
Kuo et al
operation based on the location within the pancreas. For lesions located in the head,
uncinate, or neck of the pancreas, pancreaticoduodenectomy can be performed. For
lesions located in the body or tail of the pancreas, distal pancreatectomy can be performed. For lesions in the neck and proximal body, either an extended pancreaticoduodenectomy or extended distal pancreatectomy may be performed depending on
the specific anatomy. For select lesions in the neck and proximal body of the
pancreas, central pancreatectomy may be performed. Patients with evidence of metastatic hepatic disease should be considered for metastasectomy if possible. In those
patients who are not surgical candidates, early, aggressive treatment of unresectable
liver metastases using interventional techniques may improve symptom relief and
quality of life and should be considered for palliation of disease. For patients with
advanced, metastatic disease not amenable to surgical resection, somatostatin analogues and targeted therapies offer promising therapeutic alternatives for decreasing
morbidity and increasing progression-free survival.
REFERENCES
1. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26(26):4311.
2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135(5):1469.
3. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and
pancreas. Cancer 1995;75(Suppl 1):171.
4. Yao JC, Hassan M, Phan A, et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in
the United States. J Clin Oncol 2008;26(18):3063.
5. Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40(1):1.
6. Lahat G, Ben Haim M, Nachmany I, et al. Pancreatic incidentalomas: high rate of
potentially malignant tumors. J Am Coll Surg 2009;209(3):313.
7. Grimelius L, Hultquist GT, Stenkvist B. Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol
Anat Histol 1975;365(4):275.
8. Kimura W, Jimi A, Miyasaka K, et al. Immunohistochemical study of the distribution of pancreastatin in endocrine tumors of the pancreas and in normal pancreatic tissue: analysis of autopsy cases. Pancreas 1991;6(6):688.
9. Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol 2012;13(1):24.
10. Vortmeyer AO, Huang S, Lubensky I, et al. Non-islet origin of pancreatic islet cell
tumors. J Clin Endocrinol Metab 2004;89(4):1934.
11. Muniraj T, Vignesh S, Shetty S, et al. Pancreatic neuroendocrine tumors. Dis Mon
2013;59(1):5.
12. Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract
Res Clin Endocrinol Metab 2007;21(1):1.
13. Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors
(PNETs): incidence, prognosis and recent trend toward improved survival.
Ann Oncol 2008;19(10):1727.
14. de Wilde RF, Edil BH, Hruban RH, et al. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol 2012;
9(4):199.
705
706
Kuo et al
34. Boukhman MP, Karam JH, Shaver J, et al. Insulinomaexperience from 1950 to
1995. West J Med 1998;169(2):98.
35. Dromain C, Baudin E. Endocrine pancreas. J Radiol 2005;86(6 Pt 2):797
[in French].
36. Rosch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992;326(26):1721.
37. Bernstein J, Ustun B, Alomari A, et al. Performance of endoscopic ultrasoundguided fine needle aspiration in diagnosing pancreatic neuroendocrine tumors.
Cytojournal 2013;10:10.
38. Chatzipantelis P, Salla C, Konstantinou P, et al. Endoscopic ultrasound-guided
fine-needle aspiration cytology of pancreatic neuroendocrine tumors: a study
of 48 cases. Cancer 2008;114(4):255.
39. Konda VJ, Aslanian HR, Wallace MB, et al. First assessment of needle-based
confocal laser endomicroscopy during EUS-FNA procedures of the pancreas
(with videos). Gastrointest Endosc 2011;74(5):1049.
40. Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the
impact of surgical resection on survival. Cancer 2009;115(4):741.
41. Ellison TA, Olino K, Cameron JL, et al. Tumor size correlates with lymph node
metastasis in primary pancreatic endocrine neoplasms. New Orleans (LA):
The Society for Surgery of the Alimentary Tract; 2010.
42. Pitt SC, Pitt HA, Baker MS, et al. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg 2009;13(9):1692.
43. DiNorcia J, Ahmed L, Lee MK, et al. Better preservation of endocrine function
after central versus distal pancreatectomy for mid-gland lesions. Surgery
2010;148(6):1247.
44. Falconi M, Bettini R, Boninsegna L, et al. Surgical strategy in the treatment of
pancreatic neuroendocrine tumors. J Pancreas 2006;7(1):150.
45. Lee LC, Grant CS, Salomao DR, et al. Small, nonfunctioning, asymptomatic
pancreatic neuroendocrine tumors (PNETs): role for nonoperative management.
Surgery 2012;152(6):965.
46. Gagner M, Pomp A, Herrera MF. Early experience with laparoscopic resections
of islet cell tumors. Surgery 1996;120(6):1051.
47. Venkat R, Edil BH, Schulick RD, et al. Laparoscopic distal pancreatectomy is
associated with significantly less overall morbidity compared to the open
technique: a systematic review and meta-analysis. Ann Surg 2012;255(6):
1048.
48. Gagner M, Pomp A. Laparoscopic pylorus-preserving pancreatoduodenectomy. Surg Endosc 1994;8(5):408.
49. Nakamura M, Nakashima H. Laparoscopic distal pancreatectomy and pancreatoduodenectomy: is it worthwhile? A meta-analysis of laparoscopic pancreatectomy. J Hepatobiliary Pancreat Sci 2013;20(4):421.
50. Cirocchi R, Partelli S, Coratti A, et al. Current status of robotic distal pancreatectomy: a systematic review. Surg Oncol 2013;22(3):201.
51. Cirocchi R, Partelli S, Trastulli S, et al. A systematic review on robotic pancreaticoduodenectomy. Surg Oncol 2013;22(4):23846.
52. Kulke MH, Benson AB 3rd, Bergsland E, et al. Neuroendocrine tumors. J Natl
Compr Canc Netw 2012;10(6):724.
53. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003;12(1):231.
54. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does
aggressive management improve survival? Ann Surg 2005;241(5):776.
55. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190(4):432.
56. Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors.
Gastroenterol Clin North Am 2012;41(1):119.
57. Minter RM, Simeone DM. Contemporary management of nonfunctioning pancreatic neuroendocrine tumors. J Gastrointest Surg 2012;16(2):435.
58. Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21(1):131.
59. Le Treut YP, Gregoire E, Belghiti J, et al. Predictors of long-term survival after
liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 2008;8(6):1205.
60. Gregoire E, Le Treut YP. Liver transplantation for primary or secondary endocrine tumors. Transpl Int 2010;23(7):704.
61. Wang C, Xu H, Chen H, et al. Somatostatin stimulates intestinal NHE8
expression via p38 MAPK pathway. Am J Physiol Cell Physiol 2011;300(2):
C375.
62. Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.
Cancer Control 2011;18(2):127.
63. Teunissen JJ, Kwekkeboom DJ, de Jong M, et al. Endocrine tumours of the
gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res
Clin Gastroenterol 2005;19(4):595.
64. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in
neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43(5):
610.
65. Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptor-targeted
radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40(1):173.
66. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the
control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27(28):
4656.
67. Demirkan BH, Eriksson B. Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol 2012;23(5):427.
68. Forrer F, Valkema R, Kwekkeboom DJ, et al. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007;21(1):
111.
69. Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol 2011;12(2):136.
70. Moertel CG, Kvols LK, OConnell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68(2):
227.
71. Wang L, Ignat A, Axiotis CA. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive
loss of PTEN expression in poorly differentiated neuroendocrine neoplasms.
Appl Immunohistochem Mol Morphol 2002;10(2):139.
72. Kulke MH. Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr Relat Cancer 2007;14(2):207.
707
708
Kuo et al
73. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514.
74. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with
advanced neuroendocrine tumors. J Clin Oncol 2008;26(20):3403.
75. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of
pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501.
76. Kunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic
neuroendocrine tumors. Clin Exp Gastroenterol 2010;3:7986.
77. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth
factor in digestive neuroendocrine tumours. Histopathology 1998;32(2):133.
78. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in
advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol
2008;26(8):1316.